APOMORPHINE Drug Patent Profile
✉ Email this page to a colleague
When do Apomorphine patents expire, and when can generic versions of Apomorphine launch?
Apomorphine is a drug marketed by Tp Anda Holdings and is included in one NDA.
The generic ingredient in APOMORPHINE is apomorphine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Apomorphine
A generic version of APOMORPHINE was approved as apomorphine hydrochloride by TP ANDA HOLDINGS on February 23rd, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for APOMORPHINE?
- What are the global sales for APOMORPHINE?
- What is Average Wholesale Price for APOMORPHINE?
Summary for APOMORPHINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for APOMORPHINE |
| DailyMed Link: | APOMORPHINE at DailyMed |
US Patents and Regulatory Information for APOMORPHINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tp Anda Holdings | APOMORPHINE HYDROCHLORIDE | apomorphine hydrochloride | INJECTABLE;SUBCUTANEOUS | 212025-001 | Feb 23, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
